VBI Vaccines receives positive response from Health Canada for Sci-B-Vac™ phase III trial
VBI Vaccines announced the Biologics and Genetic Therapies Directorate of Health Canada expressed its general support and acceptance of the company’s development path for its Sci-B-Vac™ vaccine, a prophylactic vaccine against hepatitis B, in a pre-Clinical Trial Application meeting. February 22, 2017